Skip to content

Mekinist 2 mg film-coated tablets

DRUG14 trials

Sponsors

Princess Maxima Center For Pediatric Oncology, Novartis Pharma AG, Bristol-Myers Squibb Services Unlimited Company, Oslo University Hospital HF, Les Hopitaux Universitaires De Strasbourg

Conditions

Acute Lymphoblastic LeukemiaAcute myeloid leukemiaAdult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumorsAdvanced CancerAdvanced solid tumorCancerChildren and Adolescents with Cancers Harboring V600 mutation.Chronic myelomonocyte leukemia

Phase 1

Phase 2

A randomized and controlled phase II protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a newly diagnosed low grade glioma with wild type BRAF gene comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine for 18 months. PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy)
RecruitingCTIS2023-508531-30-00
Les Hopitaux Universitaires De Strasbourggrade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA)
Start: 2024-03-25Target: 134Updated: 2025-09-03
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Bristol-Myers Squibb Services Unlimited CompanyPan tumor
Start: 2020-05-05Target: 307Updated: 2026-01-19
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.
RecruitingCTIS2024-513429-21-00
Cancer Trials IrelandMetastatic refractory Pancreatic Cancer
Start: 2023-06-27Target: 22Updated: 2025-07-07
Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Oslo University Hospital HFCancer
Start: 2021-04-01Target: 6000Updated: 2026-01-22
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
CompletedCTIS2023-509092-16-00
Akershus University HospitalAcute myeloid leukemia, Chronic myelomonocyte leukemia, Myelodysplastic syndrome
End: 2025-11-27Target: 33Updated: 2024-10-18
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Active, not recruitingCTIS2024-519070-39-00
Region HovedstadenMetastatic non-clear cell renal cell carcinoma
Start: 2020-03-06Target: 30Updated: 2024-10-31
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
HUS-YhtymaeAdvanced Cancer
Target: 250Updated: 2024-11-06
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.
RecruitingCTIS2024-513779-42-02
Oslo University Hospital HFCancer
Start: 2025-03-27Target: 100Updated: 2025-10-10

Phase 3

Phase 4

Related Papers